Abstract
BackgroundWhile clinical trials in systemic sclerosis-related interstitial lung disease (SSc-ILD) have traditionally used FVC% predicted as the primary outcome, combining individual outcomes may lead to a more comprehensive measure of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
